Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | MIF | P14174 | 5/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919171 | 0.78 | BRD4 (0.36) | BRD4 | |
| SCHEMBL2911129 | 0.78 | BRD4 (0.46) | BRD4MIFHDAC6LTA4HSMN1; SMN2 | |
| SCHEMBL24197361 | 0.77 | BRD4 (0.50) | BRD4TSHRGAAHSD17B10MGAM | |
| SCHEMBL2036054 | 0.77 | — | — | |
| SCHEMBL26647720 | 0.77 | BRD4 (0.50) | BRD4TSHRGAAHSD17B10MGAM | |
| SCHEMBL1858152 | 0.75 | — | — | |
| Ammonia Solution, Strong SCHEMBL27687914 | 0.74 | — | — | |
| SCHEMBL5378578 | 0.74 | — | — | |
| SCHEMBL2919627 | 0.73 | BRD4 (0.38) | BRD4TSHRGAA | |
| SCHEMBL2920789 | 0.73 | BRD4 (0.38) | BRD4TSHRGAAHSD17B10LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731520-A1 | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 | OSI Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| US-6686366-B1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | claimed |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | claimed |
| EP-1246623-A4 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2003-05-14 | — | — | EP | claimed |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | claimed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | claimed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | claimed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| WO-2012125400-A1 | COMPOSITIONS AND METHODS USING ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY EYE DISEASES | ACORN BIOMEDICAL, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1731520-A1 | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 | OSI Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-6878716-B1 | Compounds specific to adenosine A1 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1347980-A4 | COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6686366-B1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002057267-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | ADORA2A, ADORA3, ADORA1 | BRD4 1109/4885TSHR 409/4885GAA 1734/4885 |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | ADORA2A, ADORA2B, ADORA3 | BRD4 2677/4885TSHR 200/4885GAA 630/4885 |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | BRD4 3127/4885TSHR 323/4885GAA 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.